FindTrial
Sign In

Study of prevention in aspirin ulcer of the gastro-duodenum

Study of prevention in aspirin ulcer of the gastro-duodenum - Prevention study of aspirin ulcer

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000000761
Enrollment
250
Registered
2009-08-01
Start date
2005-11-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients taking aspirin

Interventions

1 year lansoplazole:15mg/day 1 year famotidine:40mg/day

Sponsors

Second Department of Internal Medicine, Showa University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients taking low-dose aspirin, age range (20-85 year-old)

Exclusion criteria

Exclusion criteria: Patients were excluded the following criteria: inadequate organ functions, pregnancy, uncontrolable DM, malignancy, state after gastrectomy, and receiving stereid or warfarin.

Design outcomes

Primary

MeasureTime frame
presence of gastro-duodenal erosion or ulcer in endoscopic examination—

Secondary

MeasureTime frame
estimation of Hericobactor pyroli—

Countries

Japan

Contacts

Public ContactKazuo Konishi

Showa University School of MedicineShowa University School of Medicine Second Department of Internal Medicine

konishigi66@aol.com03-3784-8535

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026